Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Tokyo Gov't Preparing for Switch to New Drug Manufacturing/Marketing System
February 14, 2005
- Opinions Invited on Changes in Fees for Regulatory Procedures
February 14, 2005
- REGULATORY NEWS IN BRIEF
February 14, 2005
- MEETING
February 14, 2005
- Failure to Act Damaging Weak Sector: Mr Mitchum of EFPIA Japan
February 14, 2005
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
February 14, 2005
- DIAGNOSTIC NEWS IN BRIEF
February 14, 2005
- RESEARCH & DEVELOPMENT NEWS IN BRIEF
February 14, 2005
- Preparations for Merger Going Smoothly: Mr Miyatake of Dainippon
February 14, 2005
- PRESS SEMINAR
February 14, 2005
- Sumitomo Sets Up Merger Subcommittees
February 14, 2005
- BULLETIN
February 14, 2005
- BUSINESS NEWS IN BRIEF
February 14, 2005
- Astellas to Start Out with 16,500 Employees Worldwide
February 14, 2005
- WEBSITE NEWS
February 14, 2005
- 1st 3Qtrs Business Results -1-
February 14, 2005
- 1st 3Qtrs Business Results -2-
February 14, 2005
- Annual Business Results
February 14, 2005
- Semiannual Business Results
February 14, 2005
- BULLETIN
February 7, 2005
ページ
Strategic Talent Acquisition in the Japanese Life Sciences Sector: Your Market Intelligence Briefing
Focus: How to Get the Talent You Need in a Tough MarketThe Japanese life sciences sector presents a challenging landscape for global companies. To succeed, you must move beyond reactive hiring and adopt a truly strategic talent acquisition model. Our…
Japan’s FY2026 drug price revision, officially announced on March 5, has landed poorly with the pharmaceutical industry — and the…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…